Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million
November 03, 2022 07:00 ET
|
Kura Oncology, Inc.
– $25 million equity investment from Bristol Myers Squibb at $18.25 per share – – Term loan facility from Hercules Capital provides up to $125 million – – Proceeds extend Kura’s cash runway into...
Kura Oncology to Participate in Two Upcoming Investor Conferences
November 02, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Third Quarter 2022 Financial Results
October 27, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
October 26, 2022 07:30 ET
|
Kura Oncology, Inc.
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data support potential to address ~45% of HNSCC tumors...
Kura Oncology to Participate in H.C. Wainwright Global Investment Conference
September 01, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Second Quarter 2022 Financial Results
August 03, 2022 16:03 ET
|
Kura Oncology, Inc.
– Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – ...
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
August 02, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Second Quarter 2022 Financial Results
July 27, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Three Upcoming Investor Conferences
May 26, 2022 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2022 Financial Results
May 04, 2022 16:05 ET
|
Kura Oncology, Inc.
– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in...